|
ASCC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62458935193399E-12 |
| Normal-vs-Stage2 |
7.788200E-04 |
| Normal-vs-Stage3 |
4.63450000598442E-09 |
| Normal-vs-Stage4 |
1.87240000004696E-06 |
| Stage1-vs-Stage2 |
1.140190E-01 |
| Stage1-vs-Stage3 |
2.944400E-01 |
| Stage1-vs-Stage4 |
3.775600E-01 |
| Stage2-vs-Stage3 |
4.518200E-01 |
| Stage2-vs-Stage4 |
5.364200E-01 |
| Stage3-vs-Stage4 |
9.399800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
1.157490E-04 |
| Normal-vs-Asian |
3.78960000000372E-05 |
| Caucasian-vs-AfricanAmerican |
6.336200E-01 |
| Caucasian-vs-Asian |
1.830370E-01 |
| AfricanAmerican-vs-Asian |
1.662230E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.70870034472182E-10 |
| Normal-vs-Female |
1.11022302462516E-16 |
| Male-vs-Female |
2.668800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(41-60Yrs) |
1.00890407139786E-11 |
| Normal-vs-Age(61-80Yrs) |
1.805999999549E-07 |
| Normal-vs-Age(81-100Yrs) |
8.586400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.246400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.569700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.823800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.602800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.330600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.340600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.703200E-01 |
| Classical-VS-Follicular |
2.87070001103729E-09 |
| Classical-VS-Other |
1.794370E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.449200E-04 |
| Tall-VS-Other |
1.550780E-01 |
| Tall-VS-Normal |
1.41019999999603E-06 |
| Follicular-VS-Other |
6.185800E-01 |
| Follicular-VS-Normal |
1.009780E-02 |
| Other-VS-Normal |
2.749700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.99330013500787E-10 |
| Normal-vs-N1 |
2.43849999999046E-05 |
| N0-vs-N1 |
5.617600E-01 |
|
|
